AnalystsRyan DeschnerRyan Deschner's Stock Forecasts
AnalystsRyan Deschner
Sectors:
Industries:
Analyst Ranking
Top 16%
#770 out of 4995 analysts
Average Return
+48.93%
Win Rate
84%16 out of 19
Risk vs Reward
Poor
Good
Ryan Deschner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inozyme Pharma IncINZY | +270.37% | $1.08 | $4.00 | 2025-03-12 - 2025-07-01 | Buy |
Liquidia CorpLQDA | +183.15% | $9.79 | $27.72 | 2024-08-19 - 2025-08-18 | Strong Buy |
Trevi Therapeutics IncTRVI | +138.92% | $3.16 | $7.55 | 2024-08-30 - 2025-08-22 | Buy |
Liquidia CorpLQDA | +83.91% | $14.11 | $25.95 | 2024-08-16 - 2025-08-15 | Buy |
Liquidia CorpLQDA | +75.88% | $15.26 | $26.84 | 2025-05-09 - 2025-08-22 | Strong Buy |
Ryan Deschner Analyst Color
Get additional color on Ryan Deschner's coverage of popular stocks
Ryan Deschner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Liquidia CorpLQDA | 4 | Strong Buy | $41.00 | +52.76% | Maintains | 13 days ago |
Trevi Therapeutics IncTRVI | 3 | Strong Buy | $27.00 | +257.62% | Maintains | 18 days ago |
Palvella Therapeutics IncPVLA | 1 | Buy | $54.00 | +1.09% | Initiates Coverage On | 20 days ago |
Ardelyx IncARDX | 2 | Buy | $12.00 | +96.40% | Maintains | 21 days ago |
Apellis Pharmaceuticals IncAPLS | 2 | Buy | $50.00 | +78.76% | Maintains | 25 days ago |
Viking Therapeutics IncVKTX | 1 | Strong Buy | $122.00 | +369.23% | Maintains | a month ago |
Tvardi Therapeutics IncTVRD | 1 | Buy | $62.00 | +121.03% | Initiates Coverage On | a month ago |
Inozyme Pharma IncINZY | 2 | Hold | $4.00 | 0.00% | Downgrades | 3 months ago |
Ars Pharmaceuticals IncSPRY | 3 | Strong Buy | $28.00 | +107.41% | Maintains | 7 months ago |
Omega Therapeutics IncOMGAQ | 1 | Buy | $12.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.